Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Use of Exhaled Particles to Assess Lung PharmacokineticsCompleted
NCT04914273NAUpdated Oct 15, 2024
Sponsor: Fraunhofer-Institute of Toxicology and Experimental Medicine
Healthy · Lung Pharmacokinetic
Germany
Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 DiabetesCompleted
NCT02987738Phase 1Updated Oct 15, 2024
Sponsor: Kinderkrankenhaus auf der Bult
Type1diabetes
Germany
AZD8601 Study in CABG PatientsCompleted
NCT03370887Phase 2Updated Oct 10, 2024
Sponsor: AstraZeneca
Heart Failure
United States, Finland, Germany, Netherlands, Sweden
Observational Study of Obstructive Lung Disease (NOVELTY)Completed
NCT02760329N/AUpdated Oct 3, 2024
Sponsor: AstraZeneca
Asthma · COPD · Chronic Obstructive Pulmonary Disease
United States, Argentina, Australia, Brazil, Canada +14 more
Register Schweres Asthma - German Asthma Net e.V.Recruiting
NCT06035289N/AUpdated Oct 2, 2024
Sponsor: German Asthma Net e.V.
Severe Asthma
Germany
Impact of Body Weight and Weight Loss on Drug Bioavailability, Cardiovascular Risk Factors and Metabolic BiomarkersActive Not Recruiting
NCT02386917NAUpdated Oct 2, 2024
Sponsor: The Hospital of Vestfold
Obesity
Norway
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid TumoursTerminated
NCT05397171Phase 1, Phase 2Updated Oct 1, 2024
Sponsor: AstraZeneca
Urinary Bladder Neoplasms · Colorectal Cancer · Carcinoma, Non-Small-Cell Lung
United States, Canada
Olaparib in Treating Patients With Stage IV Pancreatic CancerCompleted
NCT02677038Phase 2Updated Oct 1, 2024
Sponsor: M.D. Anderson Cancer Center
Metastatic Pancreatic Adenocarcinoma · Pancreatic Ductal Adenocarcinoma · Stage IV Pancreatic Cancer AJCC v6 and v7
United States
Trial of Olaparib in Combination With AZD5363 (ComPAKT)Completed
NCT02338622Phase 1Updated Sep 26, 2024
Sponsor: Royal Marsden NHS Foundation Trust
Advanced Cancer
United Kingdom
A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.Completed
NCT02193633Phase 1Updated Sep 26, 2024
Sponsor: Royal Marsden NHS Foundation Trust
Advanced Cancer
United Kingdom
Combination Study of AZD5069 and Enzalutamide.Terminated
NCT03177187Phase 1, Phase 2Updated Sep 26, 2024
Sponsor: Institute of Cancer Research, United Kingdom
Metastatic Castration Resistant Prostate Cancer
Switzerland, United Kingdom
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase InhibitorsCompleted
NCT02028507Phase 3Updated Sep 25, 2024
Sponsor: Spanish Breast Cancer Research Group
Metastatic Breast Cancer
Austria, Hungary, Israel, Spain
CARE Initiative: Real-world Emulation of the PALOMA-2 TrialCompleted
NCT06607601N/AUpdated Sep 23, 2024
Sponsor: Aetion, Inc.
Metastatic Breast Cancer
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]Completed
NCT06607393N/AUpdated Sep 23, 2024
Sponsor: Aetion, Inc.
Metastatic Nonsmall Cell Lung Cancer
A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian CancerCompleted
NCT05775549N/AUpdated Sep 20, 2024
Sponsor: AstraZeneca
Advanced Ovarian Cancer
United States
Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic CancerCompleted
NCT04156087Phase 2Updated Sep 19, 2024
Sponsor: Baki Topal
Pancreatic Cancer Non-resectable
Belgium
WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck CancerCompleted
NCT03028766Phase 1Updated Sep 19, 2024
Sponsor: University of Birmingham
Hypopharynx Squamous Cell Carcinoma · Oral Cavity Squamous Cell Carcinoma · Larynx Cancer
United Kingdom
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in AdultsCompleted
NCT04973449Phase 2, Phase 3Updated Sep 19, 2024
Sponsor: AstraZeneca
COVID-19 · SARS-CoV-2
Brazil, Poland, South Africa, United Kingdom
Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive TumoursCompleted
NCT02454933Phase 3Updated Sep 19, 2024
Sponsor: AstraZeneca
Locally Advanced or Metastatic EGFR T790M+ NSCLC
Canada, South Korea, Taiwan
Efficacy and Safety of MEDI7352 in Participants With Painful Diabetic NeuropathyTerminated
NCT03755934Phase 2Updated Sep 19, 2024
Sponsor: AstraZeneca
Painful Diabetic Neuropathy
Denmark, Hungary, Poland, Romania, United Kingdom
eVusheld Assessment reaL wORld Effectiveness in DoD Health SystemCompleted
NCT05569408N/AUpdated Sep 19, 2024
Sponsor: AstraZeneca
COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
United States
A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy VolunteersCompleted
NCT06304961Phase 1Updated Sep 19, 2024
Sponsor: AstraZeneca
Healthy Participants
Germany
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]Completed
NCT06585189N/AUpdated Sep 5, 2024
Sponsor: Aetion, Inc.
Metastatic Non Small Cell Lung Cancer
SCION: SABR and Checkpoint Inhibition of NSCLCWithdrawn
NCT04944173Phase 2Updated Sep 3, 2024
Sponsor: University of British Columbia
Non Small Cell Lung Cancer · Carcinoma, Non-Small-Cell Lung · Non-small Cell Lung Cancer Stage I · Lung Cancer
Canada
VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIACompleted
NCT05135455N/AUpdated Sep 3, 2024
Sponsor: AstraZeneca
Prevention of Infectious Disease Caused by SARS-CoV-2
Japan

Previous page Next page